Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

33.3%

1 terminated/withdrawn out of 3 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

67%

2 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 3
2(100.0%)
2Total
Phase 3(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT05600218Unknown

RWD Patients With Pulmonary Arterial Hypertension Treated With IP Prostacyclin Receptor Agonists

Role: collaborator

NCT02708771Phase 3Completed

Effect of W-3 Polyunsaturated Fatty Acids on Serum Albumin Concentration in Patients With Acute Heart Failure, Hypoalbuminemia, and High Inflammatory Activity

Role: lead

NCT01472237Phase 3Terminated

Nutritional Intervention Program in Malnourished Patients Admitted for Heart Failure

Role: lead

All 3 trials loaded